Bijl HA - Search Results

1

Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN, Woody J. van Dullemen HM, et al. Among authors: bijl ha. Gastroenterology. 1995 Jul;109(1):129-35. doi: 10.1016/0016-5085(95)90277-5. Gastroenterology. 1995. PMID: 7797011 Clinical Trial.

2

CD4 antibody treatment in patients with active Crohn's disease: a phase 1 dose finding study.

Stronkhorst A, Radema S, Yong SL, Bijl H, ten Berge IJ, Tytgat GN, van Deventer SJ. Stronkhorst A, et al. Gut. 1997 Mar;40(3):320-7. doi: 10.1136/gut.40.3.320. Gut. 1997. PMID: 9135519 Free PMC article.

3

Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis.

Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Bijl H, Woody JN. Elliott MJ, et al. Lancet. 1994 Oct 22;344(8930):1125-7. doi: 10.1016/s0140-6736(94)90632-7. Lancet. 1994. PMID: 7934495 Clinical Trial.

4

Anti-CD4 Therapy Decreases Epithelial Expression of HLA-DR Molecules in Patients with Crohn's Disease.

Radema SA, Stronkhorst A, Bijl H, Tytgat GN, van Deventer SJ. Radema SA, et al. Inflamm Bowel Dis. 1995 Fall;1(3):193-7. Inflamm Bowel Dis. 1995. PMID: 23282389

5

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha.

Elliot MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katasikis P, Brennan FM, Bijl H, Ghrayeb J, Woody JN. Elliot MJ, et al. Arthritis Rheum. 2008 Feb;58(2 Suppl):S92-S101. doi: 10.1002/art.23362. Arthritis Rheum. 2008. PMID: 18240199 Free article.

6

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha.

Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, Brennan FM, Walker J, Bijl H, Ghrayeb J, et al. Elliott MJ, et al. Arthritis Rheum. 1993 Dec;36(12):1681-90. doi: 10.1002/art.1780361206. Arthritis Rheum. 1993. PMID: 8250987

7

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis.

Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, Macfarlane JD, Bijl H, et al. Elliott MJ, et al. Lancet. 1994 Oct 22;344(8930):1105-10. doi: 10.1016/s0140-6736(94)90628-9. Lancet. 1994. PMID: 7934491 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

7 results

Search Page

Filters